Literature DB >> 25962477

Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.

Wu Li1, Min Li1, Guangcun Deng1, Liping Zhao2, Xiaoming Liu1, Yujiong Wang1.   

Abstract

Tuberculosis (TB) remains to be a prevalent health issue worldwide. At present, Mycobacterium bovis Bacillus Calmette Guerin (BCG) is the singular anti-TB vaccine available for the prevention of disease in humans; however, this vaccine only provides limited protection against Mycobacterium tuberculosis (Mtb) infection. Therefore, the development of alternative vaccines and strategies for increasing the efficacy of vaccination against TB are urgently required. The present study aimed to evaluate the ability of a recombinant adenoviral vector (Ad5-CEAB) co-expressing 10-kDa culture filtrate protein, 6-kDa early-secreted antigenic target, antigen 85 (Ag85)A and Ag85B of Mtb to boost immune responses following primary vaccination with BCG in mice. The mice were first subcutaneously primed with BCG and boosted with two doses of Ad5-CEAB via an intranasal route. The immunological effects of Ad5-CEAB boosted mice primed with BCG were then evaluated using a series of immunological indexes. The results demonstrated that the prime-boost strategy induced a potent antigen-specific immune response, which was primarily characterized by an enhanced T cell response and increased production of cytokines, including interferon-γ, tumor necrosis factor-α and interleukin-2, in mice. In addition, this vaccination strategy was demonstrated to have an elevated humoral response with increased concentrations of antigen-specific bronchoalveolar lavage secretory immunoglobulin (Ig)A and serum IgG in mice compared with those primed with BCG alone. These data suggested that the regimen of subcutaneous BCG prime and mucosal Ad5-CEAB boost was a novel strategy for inducing a broad range of antigen-specific immune responses to Mtb antigens in vivo, which may provide a promising strategy for further development of adenoviral-based vaccine against Mtb infection.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25962477     DOI: 10.3892/mmr.2015.3770

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.

Authors:  Fu-Ying Dai; Jun-Fang Wang; Xue-Li Gong; Lang Bao
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 2.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

3.  A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis.

Authors:  Razieh Dalirfardouei; Mohsen Tafaghodi; Zahra Meshkat; Adel Najafi; Aida Gholoobi; Maryam Sadat Nabavinia; Samineh Sajedifar; Mojtaba Meshkat; Ali Badiee; Mohammad Ramezani; Abdol-Reza Varasteh; Mahboubeh Naderinasab
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

Review 4.  A review of the BCG vaccine and other approaches toward tuberculosis eradication.

Authors:  Thomas Cho; Christopher Khatchadourian; Huy Nguyen; Yash Dara; Shuna Jung; Vishwanath Venketaraman
Journal:  Hum Vaccin Immunother       Date:  2021-03-26       Impact factor: 3.452

Review 5.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

6.  Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models.

Authors:  A P Tkachuk; V A Gushchin; V D Potapov; A V Demidenko; V G Lunin; A L Gintsburg
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

7.  The immunological impact of adenovirus early genes on vaccine-induced responses in mice and nonhuman primates.

Authors:  Kotou Sangare; Iskra Tuero; Mohammad Arif Rahman; Tanya Hoang; Leia K Miller-Novak; Diego A Vargas-Inchaustegui; David J Venzon; Celia LaBranche; David C Montefiori; Marjorie Robert-Guroff; Michael A Thomas
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

8.  Towards Reverse Vaccinology for Bovine TB: High Throughput Expression of Full Length Recombinant Mycobacterium bovis Proteins.

Authors:  Deepa Paliwal; Michelle Thom; Areej Hussein; Divyashree Ravishankar; Alex Wilkes; Bryan Charleston; Ian M Jones
Journal:  Front Mol Biosci       Date:  2022-08-11

9.  Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin.

Authors:  Erkko Ylösmäki; Manlio Fusciello; Beatriz Martins; Sara Feola; Firas Hamdan; Jacopo Chiaro; Leena Ylösmäki; Matthew J Vaughan; Tapani Viitala; Prasad S Kulkarni; Vincenzo Cerullo
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

10.  EXPRESSION OF IMMUNOGLOBULIN, GRANZYME-B AND PERFORIN AGAINST Ag85A AND Ag85B PROTEINS OF MYCOBACTERIUM TUBERCULOSIS IN BALB/C MICE.

Authors:  Wayan Tunas Artama; Tri Wibawa; Ni Made Mertaniasih
Journal:  Afr J Infect Dis       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.